Umifenovir addition gives no significant clinical benefit in COVID-19 treatment: Glenmark study
The FAITH study enrolled a total of 158 hospitalised patients with moderate COVID-19 in India
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
FAITH trial
Glenmark to launch FabiFlu (400 mg) for COVID-19 treatment
With the new 400 mg version, patients need to consume nine tablets on Day 1, and thereafter two tablets twice a day from Day 2…